Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
November 2017
-
Story Discovery
Small viruses could accelerate cell and gene therapy research
Novartis collaborates with Homology Medicines to adapt and refine genome editing technology.
-
Press Release
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD AMG 334 has a… -
Press Release
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
Entresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common… -
Press Release
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
Poor patients in Punjab will have access to high-quality medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will… -
Key Release
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-… -
Story Patient Perspectives
Conversations with Patient Advocates: Ron Hollander, president of INCA
Ron Hollander, president of the International Neuroendocrine Cancer Alliance, talks to us about patient advocacy.
-
Press Release
Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
MONALEESA-7 met primary endpoint of progression-free survival, demonstrating superior efficacy of Kisqali combination therapy vs. endocrine treatment alone in first-line treatment of premenopausal… -
Press Release
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study[1] PsA can lead to reduced… -
Press Release
Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years
For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx® have no radiographic progression of the spine at 4 years[1] These new data… -
Press Release
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
Application follows sBLA submission to the FDA for r/r DLBCL which marked second US application for first-ever FDA approved CAR-T therapy Building on the US r/r B-cell ALL experience, Novartis… -
Story Patient Perspectives
Targeting the roots of Sjögren’s syndrome
Early clinical trial reports results in this hidden disease
-
Press Release
Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
Parties to collaborate on a new Generation Study 2, assessing whether investigational drug CNP520 can prevent or delay the symptoms of Alzheimer's disease (AD) Clinical trial is part of the…